Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EBMT 2021

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 14-17, 2021

As official media partners, VJHemOnc is excited to bring you the latest news from the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), which was held virtually from 14-17 of March, 2021.

Latest Videos

View all
1:49
Looking forward to the EBMT 2021 Annual Meeting
Nicolaus Kröger • 27 Jan 2021
3:13
Prednisone with or without ECP for GvHD
Daniel Couriel • 9 Mar 2021
1:22
REACT: ELISPOT assay predicts CMV reactivation in allo-HSCT patients
Roy Chemaly • 8 Mar 2021
3:13
HORIZON: melflufen plus dexamethasone shows efficacy in R/R myeloma
Maria-Victoria Mateos • 10 Mar 2021

Multiple Myeloma

View all
4:28
Cellular therapy: changing clinical practice for treatment of myeloma
Maria-Victoria Mateos • 10 Mar 2021
4:17
CAR-T for myeloma: ide-cel pending FDA approval
Nikhil Munshi • 22 Mar 2021

AML

View all
2:13
allo-SCT in refractory AML: FLAMSA approaches
Mohamad Mohty • 24 Feb 2021
1:35
FLT3 inhibitor maintenance after allo-SCT for AML
Nicolaus Kröger • 4 Mar 2021

ALL

View all
3:58
Omidubicel versus standard UCB transplantation
Guillermo Sanz • 8 Mar 2021
4:21
Haploidentical versus unrelated transplant in ALL
Arnon Nagler • 4 Mar 2021

Lymphoma

View all
1:33
CAR-T moving forwards for r/r DLBCL
Anna Sureda • 19 Mar 2021
5:14
MABs for Hodgkin lymphoma
Ali Bazarbachi • 12 Mar 2021

MRD

View all
1:38
Value of MRD in patients with NPM1-mutated AML
Farhad Ravandi • 11 Mar 2021
8:03
Latest developments in transplant for AML
Arnon Nagler • 4 Mar 2021
5:18
Response monitoring in multiple myeloma
Meral Beksac • 18 Mar 2021
3:15
Novel agents for consolidation after auto-SCT in myeloma
Nico Gagelmann • 16 Mar 2021

Immuno-Oncology

View all
6:15
Impact of novel therapies on post-transplant infection risk
Livio Pagano • 8 Mar 2021
1:25
Real-world data on CAR-T therapy for B-ALL
Stephan Grupp • 18 Mar 2021
4:02
The future of CAR-T and cellular therapy
Christian Chabannon • 12 Mar 2021
3:17
TGFb-resistant NK cells for hematological malignancies
Catherine Bollard • 23 Mar 2021
The content of VJHemOnc is intended for healthcare professionals